WB
e Expression of PAI-1 in BMMSCs was significantly increased following treatment with any concentration of GC, as shown by qRT-PCR and western blotting.WB
b Expression of PAI-1 in VSMCs was increased by GC treatment and by GB-Exo treatment, as shown by qRT-PCR and c western blotting results.e qRT-PCR and f western blotting also demonstrated that overexpressed PAI-1 was detected in GC-treated and GB-Exo groups in VECs. In particular, GB-Exo groups exhibited dramatically upregulated PAI-1 expression in VECs.WB
f qRT-PCR results demonstrated that the expression levels of PAI-1 were reduced by treatment with miR-133b-3p mimics and increased by treatment with an miR-133b-3p inhibitor in VECs, which was also verified by western blotting (g).| Product Name | PAI-1 antibody |
|---|---|
| Antibody Type | Primary Antibodies |
| Product description | Mouse Monoclonal antibody to PAI-1 [H34G6] |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG |
| Clone Number | H34G6 |
| Host Species | Mouse |
| Tested Applications | ELISAWB |
| Not yet tested in other applications. Optimal dilutions should be determined experimentally by the researcher.: |
|
| Species Reactivity | MousePigRabbitRat |
| Concentration | 1mg/ml |
| Purification | Affinity purified |
| Gene Synonyms | PAI1 PAI 1 |
|---|---|
| Target | Recognizes Plasminogen Activator Inhibitor 1 (PAI-1) |
WB
e Expression of PAI-1 in BMMSCs was significantly increased following treatment with any concentration of GC, as shown by qRT-PCR and western blotting.
WB
b Expression of PAI-1 in VSMCs was increased by GC treatment and by GB-Exo treatment, as shown by qRT-PCR and c western blotting results.e qRT-PCR and f western blotting also demonstrated that overexpressed PAI-1 was detected in GC-treated and GB-Exo groups in VECs. In particular, GB-Exo groups exhibited dramatically upregulated PAI-1 expression in VECs.
WB
f qRT-PCR results demonstrated that the expression levels of PAI-1 were reduced by treatment with miR-133b-3p mimics and increased by treatment with an miR-133b-3p inhibitor in VECs, which was also verified by western blotting (g).| Application Notes | Not yet tested in other applications. Optimal dilutions should be determined experimentally by the researcher.: |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | Keep as concentrated solution. Aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | 0.05M Sodium Phosphate; 0.15M NaCl; pH 7.4 |
